P2RY12 and chronic kidney disease: These findings are consistent with our published findings that the use of potent P2Y12-Is was associated with lower risk of lethal sepsis in patients on dialysis.6 These results further support our recently published hypothesis that platelets, through P2Y12 receptors and their inhibitors, modulate inflammation in CKD.4,7 In this letter, we also report that sepsis is common in patients with CKD—nearly one in five individuals were hospitalized for sepsis within 2.6 years.